{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T12:22:56Z","timestamp":1771935776218,"version":"3.50.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-MSDPU2021-0202"],"award-info":[{"award-number":["Y-MSDPU2021-0202"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The study aimed to evaluate the effectiveness of six prognostic scores for predicting the outcomes to first-line chemoimmunotherapy (CIT) in non-small cell lung cancer (NSCLC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>NSCLC patients receiving first-line CIT were included. The prognostic scores evaluated were RMH, MDACC, MDACC+NLR, MDA-ICI, LIPI, and GRIm. Survival curves were generated using the Kaplan\u2013Meier method, and univariate and multivariate analyses were conducted via the Cox proportional hazards regression model. The C\u2212index and time\u2212dependent AUC were calculated to comprehensively quantify and compare the predictive performance of each system. The Log\u2212rank test and False Discovery Rate (FDR) correction was employed to compare survival outcomes across different risk groups defined by the six prognostic scoring systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A cohort of 298 NSCLC patients was analyzed. The median overall survival (mOS) of patients receiving first-line CIT was 36.5 months (95%CI: NE-NE), and the median progression-free survival (mPFS) was 14.5 months (95%CI: 11.9-17.1). Multivariate analysis showed that bone metastasis (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.042), and more than two metastatic sites (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.031) as independent predictors of poor OS. In quantitative performance comparison, RMH achieved the highest C-indices for both OS (0.672, 95%CI: 0.531-0.813) and PFS (0.652, 0.564-0.737); MDACC also performed well, with C-indices for OS (0.651, 0.564-0.737) and PFS (0.615, 0.554-0.738). Time-dependent AUC analysis showed that MDA-ICI attained the highest 1-year OS and PFS AUC (0.630 and 0.592), followed by the MDACC+NLR (0.600 and 0.571). Based on log-rank testing and following FDR correction, only the MDACC maintained a statistically significant association with OS (high-risk 14.0 vs. intermediate-risk 34.6 vs. low-risk NR months; P = 0.003, Q = 0.036). For PFS, the MDACC+NLR score showed a marginal significance after FDR correction (Q = 0.054).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The RMH, MDACC, and MDACC+NLR scoring systems all demonstrate prognostic utility in the NSCLC patients treated with first-line CIT, and the optimal choice among them may depend on the specific clinical context and the outcome metric of primary interest.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1695859","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T06:34:42Z","timestamp":1771310082000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of six clinical prognostic scores in NSCLC patients undergoing first line chemoimmunotherapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiaqi","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Department of Respiratory, Beijing Genertec Aerospace Hospital","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinliang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhisong","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"46","author":"Han","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12359","article-title":"Non-small cell lung cancer in China","volume":"42","author":"Chen","year":"2022","journal-title":"Cancer Commun (London England)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.3390\/jcm9082473","article-title":"Clinicopathological factors related to recurrence patterns of resected non-small cell lung cancer","volume":"9","author":"Shimizu","year":"2020","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in lung cancer: current landscape and future directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.03.020","article-title":"Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials","volume":"120","author":"Maymani","year":"2018","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.480","article-title":"Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials","volume":"118","author":"Sen","year":"2018","journal-title":"Br J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.07.027","article-title":"Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)","volume":"84","author":"Bigot","year":"2017","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604218","article-title":"Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience","volume":"98","author":"Arkenau","year":"2008","journal-title":"Br J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2217","article-title":"Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience","volume":"18","author":"Wheler","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","article-title":"Metastatic sites and survival in lung cancer","volume":"86","author":"Riihim\u00e4ki","year":"2014","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clinic Proc"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03136","article-title":"Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non-small-cell lung cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"100225","DOI":"10.1016\/j.jtocrr.2021.100225","article-title":"Pembrolizumab plus chemotherapy for chinese patients with metastatic squamous NSCLC in KEYNOTE-407","volume":"2","author":"Cheng","year":"2021","journal-title":"JTO Clin Res Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.7150\/jca.30463","article-title":"Prognostic value of site-specific metastases in lung cancer: A population based study","volume":"10","author":"Li","year":"2019","journal-title":"J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12032-018-1182-8","article-title":"Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer","volume":"35","author":"Gibson","year":"2018","journal-title":"Med Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S164700","article-title":"Clinical features of patients with lung cancer accompanied by thromboembolism or disseminated intravascular coagulation","volume":"14","author":"Kanaji","year":"2018","journal-title":"Ther Clin Risk Manage"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2013.05.002","article-title":"Determinants of survival in advanced non-small-cell lung cancer in the era of targeted therapies","volume":"14","author":"Bauml","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.893716","article-title":"Research progress on the microenvironment and immunotherapy of advanced non-small cell lung cancer with liver metastases","volume":"12","author":"Fang","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score \u2265 1% in the KEYNOTE-042 study","volume":"41","author":"de Castro","year":"2023","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00650-1","article-title":"Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1747","article-title":"Prognostic value of the lung immune prognostic index for patients treated for metastatic non-small cell lung cancer","volume":"5","author":"Kazandjian","year":"2019","journal-title":"JAMA Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2019.11.07","article-title":"Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy","volume":"8","author":"Ruiz-Ba\u00f1obre","year":"2019","journal-title":"Trans Lung Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/cancers13051176","article-title":"Value of the lung immune prognostic index in patients with non-small cell lung cancer initiating first-line atezolizumab combination therapy: subgroup analysis of the IMPOWER150 trial","volume":"13","author":"Hopkins","year":"2021","journal-title":"Cancers"},{"key":"B30","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1741-7015-8-21","article-title":"Reporting performance of prognostic models in cancer: a review","volume":"8","author":"Mallett","year":"2010","journal-title":"BMC Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00016","article-title":"Assessing the generalizability of prognostic information","volume":"130","author":"Justice","year":"1999","journal-title":"Ann Internal Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1695859\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:29:49Z","timestamp":1771932589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1695859\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1695859"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1695859","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"1695859"}}